Ex-Sanofi Genzyme chief David Meeker hops to a new biotech CEO post, this time focusing on quick leap to commercialization
Six months after Rhythm Pharmaceuticals CEO Keith Gottesdiener announced plans to exit on the heels of the biotech’s first FDA filing, the Boston-based biotech has found the experienced biopharma CEO they want to lead their hoped-for transition into commercialization.
Ex-Sanofi Genzyme chief David Meeker — who jumped from his last job as CEO of KSQ less than 2 weeks ago — has now moved on to Rhythm.
Keep reading Endpoints with a free subscription
Unlock this story instantly and join 86,800+ biopharma pros reading Endpoints daily — and it's free.